



GOVERNMENT BIOSCIENCE GRANTS

www.G2Gconsulting.com/bioscience-corner

GBG Report

Updated Monthly

June 10, 2019

	Title (Agency)	Opp. Number	Description	Deadline	Funding Level	Link
			ADDICTION/SUBSTANCE ABUSE (7)			
1.	Digital Health Technologies to Address the Social Determinants of Health in context of Substance Use Disorders (SUD) (R43/R44 & R41/R42 Clinical Trial Optional) (NIH)	RFA-DA-20-018 (R43/44) RFA-DA-20-017 (R41/42)	The purpose of this FOA is to solicit the research applications for commercializable, digital health-based products that aim at positively affecting the fundamental social and environmental conditions that are risk factors for the populations affected by the use of drugs, including opioids.	Letter of Intent Due: 6/29/19 Proposal Due: 7/29/19	Dependent upon proposal	https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-20-018.html (R43/44) https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-20-017.html (R41/42)
2.	Rapid Assessment of Drug Abuse: Smart City Tools (R41/R42 & R43/R44 Clinical Trial Optional) (NIH)	RFA-DA-20-020 (R41/42) RFA-DA-20-021 (R43/44)	The purpose of this FOA is to solicit research applications for technologies with commercialization potential that aim to improve the utilization of wastewater testing for dynamic monitoring of illicit drugs.	Letter of Intent Due: 7/7/19 Proposal Due: 8/7/19	Dependent upon proposal, for up to 2 years	https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-20-020.html (R41/42) https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-20-021.html (R43/44)

3.	Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional) (NIH)	PAR-19-282	<p style="text-align: center;">ADDICTION/SUBSTANCE ABUSE</p> <p>This FOA uses a R61/R33 Phased Innovation Award mechanism to support clinical research applications that are exploratory and developmental in nature and focus on understanding the neurobiological mechanisms underlying SUD, including fundamental brain function relevant to substance use. This FOA is particularly designed to support exploratory/developmental projects requiring budgets that would exceed that allowed for the R21 mechanism (Neuroscience Research on Drug Abuse (R21 Clinical Trial Optional))</p>	<p>Letter of Intent Due: 9/10/19</p> <p>Proposal Due: 10/10/19</p>	<p>Dependent upon proposal, for up to 5 years</p>	<p>https://grants.nih.gov/grants/guide/pa-files/PAR-19-282.html</p>
4.	National Drug Early Warning System Coordinating Center (U01 Clinical Trial Optional) (NIH)	RFA-DA-20-016	<p>This FOA solicits applications for a single Coordinating Center to support novel data acquisition strategies, data harmonization, analysis and dissemination activities on emerging and current drug abuse trends across the United States. The Coordinating Center will (1) Maintain a Scientific Advisory Group; (2) Maintain and refine an Early Warning Network composed of local experts on drug abuse data from the selected communities, as well as NIDA-supported community-based researchers, to assist in the ongoing monitoring and interpretation of data; (3) Maintain key community-level indicators for monitoring drug abuse trends and early identification of new synthetic drugs and emerging issues including establishing harmonization of indicators and of presentation and analysis of indicators across the selected communities; (4) Continue to identify and maintain novel sources of data including treatment admissions data, national drug use among adults and youth, law enforcement seizures, and drug poisoning death; (5) Conduct cross-site data analyses from the harmonized Coordinating Center data; (6) Continue to disseminate and identify novel ways to execute dissemination and publication plans of results and findings from the Coordinating Center data, including development and maintenance of a website for disseminating data and findings; (7) Conduct webinars on topics of interest to stakeholders; (8) Conduct on the ground epidemiologic investigations on topics of immediate crisis or need, providing functional feedback to impacted communities towards optimizing current and future response; (9) Provide operational, administrative and logistical support for the Coordinating Center data harmonization and dissemination initiative.</p>	<p>Letter of Intent Due: 7/14/19</p> <p>Proposal Due: 8/14/19</p>	<p>Up to \$550,000, for up to 5 years</p>	<p>http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-20-016.html</p>

5.	Notice of Intent to Publish a Funding Opportunity Announcement for The National Drug Abuse Treatment Clinical Trials Network (UG1) Clinical Trial Optional (NIH)	NOT-DA-19-047	<p style="text-align: center;">ADDICTION/SUBSTANCE ABUSE</p> <p>The National Institute on Drug Abuse (NIDA) intends to publish a FOA to solicit applications from clinical investigators to participate in the National Drug Abuse Treatment Clinical Trials Network (CTN). NIDA intends to continue to develop and test interventions for addressing the wide spectrum of substance use problems via collaborative partnerships among NIDA, clinical research investigators, healthcare providers, and institutions.</p>	Estimated Release Date: August 2019	Dependent upon proposal	https://www.grants.gov/web/grants/view-opportunity.html?opId=316665
			AGING (1)			
6.	Claude D. Pepper Older Americans Independence Centers (P30 Clinical Trial Optional) (NIH)	RFA-AG-20-019	This FOA supports applications for Claude D. Pepper Older Americans Independence Centers (OAICs), centers of excellence in geriatrics research and research education to increase scientific knowledge leading to better ways to maintain or restore independence in older persons. The OAIC awards are designed to develop or strengthen awardee institutions programs that focus and sustain progress on a key area in aging research related to the mission of the OAIC program.	Letter of Intent Due: 9/2/19 Proposal Due: 10/2/19	Up to \$950,000, for up to 5 years	https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-20-019.html
			ALZHEIMER'S DISEASE (8)			
7.	Exploratory Grant for NIA Alzheimer's Disease Research Center (P20 Clinical Trial Not Allowed) (NIH)	RFA-AG-20-023	This FOA invites applications to plan and initiate collaborative activities that will develop and implement infrastructure appropriate for an Alzheimer's Disease Research Center (P30).	Letter of Intent Due: 9/9/19 Proposal Due: 10/9/19	Up to \$750,000 per year, for up to 3 years	https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-20-023.html

8.	Oscillatory Patterns of Gene Expression in Aging and Alzheimer's Disease (R01 Clinical Trial Not Allowed) (NIH)	RFA-AG-20-040	<p style="text-align: center;">ALZHEIMER'S DISEASE</p> <p>This FOA invites applications that seek to enhance existing transcriptome and proteome data sets by revealing oscillatory patterns of gene expression in aging and in Alzheimer's disease (AD), by uncovering their molecular significance, and by identifying rhythmic gene and/or protein profiles associated with the risk for AD.</p>	<p>Letter of Intent Due: 9/23/19</p> <p>Proposal Due: 10/23/19</p>	<p>Up to \$600,000 per year, for up to 5 years</p>	<p>https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-20-040.html</p>
9.	Understanding Senescence in Brain Aging and Alzheimer's Disease (R01 Clinical Trial Not Allowed) (NIH)	RFA-AG-20-025	<p>The goal of this FOA is to support research focused on understanding the role of senescence in brain aging and in Alzheimer's disease (AD). This FOA encourages research projects addressing critical knowledge gaps in our understanding of the neurobiology of senescence through cutting-edge techniques, cross-disciplinary collaborations, and/or conceptual innovation, leveraging what is known about senescence in peripheral tissues to learn more about brain aging. Developing a clear understanding of the mechanisms driving aging processes in the brain, including senescence, is essential for combating age-related neurodegenerative diseases.</p>	<p>Letter of Intent Due: 9/17/19</p> <p>Proposal Due: 10/17/19</p>	<p>Up to \$250,000, for up to 5 years</p>	<p>https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-20-025.html</p>
10.	Limited Competition: NIA Genome Center for Alzheimer's Disease (U54 Clinical Trial Not Allowed) (NIH)	PAR-19-288	<p>This FOA invites applications to continue the operations of the NIA Genome Center for Alzheimer's Disease (GCAD) to facilitate and support the Alzheimer's Disease Sequencing Project (ADSP) activities. GCAD will serve as the focal point for all phases of ADSP quality control checking, data harmonization, and meta-analysis. The FOA is intended to support a major component of the full range of analysis for the ADSP. The spectrum of the Center's activities comprises a multidisciplinary attack on Alzheimer's Disease (AD) and AD Related Dementias (ADRD) in keeping with NIA's programmatic needs.</p>	<p>Proposal Due: 9/25/19</p>	<p>Dependent upon proposal, for up to 5 years</p>	<p>https://grants.nih.gov/grants/guide/pa-files/PAR-19-288.html</p>

11.	Interpersonal Processes in Alzheimer's Disease and Related Dementias Clinical Interactions and Care Partnerships (R01 Clinical Trial Optional) (NIH)	RFA-AG-20-006	<p style="text-align: center;">ALZHEIMER'S DISEASE</p> <p>The goal of this FOA is to support research that can lead to the development of interventions for optimizing communication among patients, caregivers, and health care practitioners, and for preserving strong and supportive caregiving relationships throughout disease progression along the continuum of care for people with AD/ADRD. To these ends, basic research and translational research is solicited in two high-priority areas: (1) effective communications and relationships among patients, healthcare practitioners, and caregivers; and (2) associations between close relationship processes and health in caregiving relationships.</p>	Letter of Intent Due: 9/23/19 Proposal Due: 10/23/19	Up to \$500,000 per year, for up to 5 years	https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-20-006.html
12.	FY19 Peer Reviewed Alzheimer's Research Program (PRARP) (CDMRP/DoD)	W81XW H-19-PRARP-CSRA; InCASA; RPA	The goal of FY19 PRARP is to support innovative, high-impact Alzheimer's research. PRARP encourages applications that address the critical needs of the Alzheimer's community in one or more of the following FY19 Focus Areas: Mechanisms of pathogenesis; Biomarkers; Quality of life; Family and caregiver support; Epidemiology; Novel target identification; Nonpharmacological interventions and devices; and Bioinformatics.	Letter of Intent Due: 6/26/19 Proposal Due: 7/17/19	Up to \$1.3 million, for up to 3 years Dependent upon award mechanism	https://cdmrp.army.mil/funding/prarp
BIOSURVEILLANCE (2)						
13.	Forecasted Opportunity: Public Health Surveillance for the Prevention of Complications of Bleeding Disorders (CDC)	CDC-RFA-DD20-2004	Since 1996 the CDC has funded the federal network of hemophilia treatment centers (HTCs) for the collection of data for the monitoring of health indicators of importance to persons with bleeding disorders. This data is used to measure rates of complications of bleeding disorders and monitor trends over time (including inhibitors and other issues of blood and treatment product safety); identify high risk populations for prevention programs; and identify issues that require research. The purpose of this FOA is to continue the surveillance for these conditions through the HTCs.	Estimated Release Date: April 2020	Dependent upon proposal	https://www.grants.gov/web/grants/view-opportunity.html?opId=316492

14.	Capacity Building for Sickle Cell Disease Surveillance (CDC)	CDC-RFA-DD19-1906	<p style="text-align: center;">BIOSURVEILLANCE</p> <p>Through this NOFO, CDC plans to fund up to seven recipients to participate in a rigorous course of activities to build capacity for a state-wide Sickle Cell Disease (SCD) surveillance system. This NOFO will improve and expand the current SCD efforts by building the capacity of states to implement the program. Each state has a unique demographic makeup, distinct health care policies, and challenges related to access to care; all of these factors play a large role in the outcomes and experiences of individuals with SCD. This NOFO builds the framework and a road map for recipients to gather unique data and conduct in-depth analyses to inform their SCD efforts and to compare and contrast SCD-related health care and health outcomes across states.</p>	Letter of Intent Due: 6/14/19 Proposal Due: 7/22/19	Dependent upon proposal, for up to 1 year	https://www.grants.gov/web/grants/view-opportunity.html?opId=315312 (Full Announcement in Related Documents Tab)
BROAD AGENCY ANNOUNCEMENTS (14)						
15.	2018 BARDA Broad Agency Announcement (HHS)	BAA-18-100-SOL-00003	This BAA is open for two years and key areas of interest include: CBRN Vaccines; Antitoxins and Therapeutic Proteins; Antibacterials; Radiological, Nuclear and Chemical Threat, and Burn Medical Countermeasures; Vaccines and Therapeutics for Influenza and Emerging Infectious Diseases; Respiratory Protective Devices; Ventilators; MCM Production Platform Systems; Modeling and Visual Analytics as Enabling Technologies for Influenza, Emerging Infectious Disease, and CBRN Threats; and Diagnostics.	White Papers Due 2018-19: 1/31, 4/30, 7/31, 10/31	Dependent upon proposal	https://www.mediccountermeasures.gov
16.	DoD USAMRMC Broad Agency Announcement for Extramural Medical Research (DoD)	W81XW H18SBA A1	This BAA supports extramural research and development ideas for basic and applied research to support scientific study and experimentation directed toward advancing the state of the art or increasing knowledge or understanding rather than focusing on development of a specific system or hardware solution. Research and development funded through this BAA are intended and expected to benefit and inform both military and civilian medical practice and knowledge. Research areas include: Military Infectious Disease Research Program; Combat Casualty Care Research Program; Military Operational Research Program; Clinical and Rehabilitative Medicine Research Program; Medical Biological Defense Research Program; Medical Chemical Defense Research Program; Medical Simulation and Information Sciences Research Program.	No Due Dates, open for the next 5 years 10/1/17 to 9/30/22 Letter of Intent and Full Proposal Required	Dependent upon proposal, for up to 5 years	https://daks2k3a4ib2z.cloudfront.net/5552187c43c8fafa28fd470c/59d29ed69c3017000141dc1c_MT_EC%20Info.pdf

17.	U.S. Army Research Institute for the Behavioral and Social Sciences (ARI) Broad Agency Announcement for Basic, Applied, and Advanced Research (DoD)	W911NF-18-S-0005	<p style="text-align: center;">BROAD AGENCY ANNOUNCEMENTS</p> <p>Programs funded under this BAA include basic research, applied research, and advanced technology development that can improve human performance and Army readiness. Funding of R&D within ARI areas of interest will be determined by funding constraints and priorities set during each budget cycle. Topic areas of basic research interest include: Understanding Team Dynamics; Improving Leadership and Leader Development; Identifying, Assessing, and Assigning Quality Personnel; Enhancing Lifelong Learning. ARI seeks Applied Research proposals that provide a systematic expansion and application of knowledge to design and develop useful strategies, techniques, methods, tests, or measures that provide the means to meet a recognized and specific Army need. Applied Research precedes specific technology investigations or development and should have high potential to transition into advanced technology.</p>	<p>No Due Dates, open for the next 5 years 4/30/18 to 4/29/23</p> <p>Full Proposal Required</p>	Dependent upon proposal	https://www.fbo.gov/index.php?s=opportunity&mode=form&id=37f3544d819fec9bcb7fa1de2b66f3af&tab=documents&tabmode=list
18.	FY19 Long Range Broad Agency Announcement (BAA) for Navy and Marine Corps Science and Technology N00014-19-S-B001 (DoD)	N00014-19-S-B001	<p>The Office of Naval Research (ONR), ONR Global (ONRG), and the Marine Corps Warfighting Lab (MCWL) are interested in receiving proposals for Long-Range Science and Technology (S&T) Projects which offer potential for advancement and improvement of Navy and Marine Corps operations. Readers should note that this is an announcement to declare ONR's broad role in competitive funding of meritorious research across a spectrum of science and engineering disciplines that include, but are not limited to: technologies to improve the medical care for Marines through prevention, protection and casualty response; sustain distributed operations in austere and remote environments; improve secure information exchange; and defend cyberspace operations and networks. The full list of research areas can be found on pages 6-12 full announcement PDF.</p>	<p>No Due Dates, Full Proposals accepted until 9/30/19</p>	Dependent upon proposal	https://www.onr.navy.mil/en/Contracts-Grants/Funding-Opportunities/Broad-Agency-Announcements
19.	The USAID Global Health Broad Agency Announcement for Research and Development (2018) (USAID)	GLOBAL HEALTH -BAA- 2018	<p>This BAA seeks opportunities to co-create, co-design, co-invest, and collaborate in the research, development, piloting, testing, and scaling of innovative, practical and cost-effective interventions to address the most pressing problems in global health. The United States Agency for International Development (USAID) invites organizations and companies to participate with USAID, in cooperation with its partners, to generate novel tools and approaches that accelerate and sustain improved health outcomes in developing countries.</p>	<p>Expression of Interest accepted on a rolling basis though 5/30/22; must be invited back for full proposal</p>	Dependent upon proposal and award type	https://www.grants.gov/web/grants/view-opportunity.html?opId=305999

20.	Air Force Office of Scientific Research Broad Agency Announcement (DoD)	FA9550-18-S-0003	<p style="text-align: center;">BROAD AGENCY ANNOUNCEMENTS</p> <p>This BAA's focus is on research areas that offer significant and comprehensive benefits to national warfighting and peacekeeping capabilities. These areas are organized and managed in two scientific branches: Engineering and Information Sciences (RTA) and Physical and Biological Sciences (RTB). Research topics in the Chemistry and Biological sciences categories include Biophysics; Human Performance and Biosystems; Mechanics of Multifunctional Materials and Microsystems; Molecular Dynamics and Theoretical Chemistry; Natural Materials, Systems, and Extremophiles; and Organic Materials Chemistry. For a full list of applicable research topics, see full solicitation.</p>	Proposals accepted on a rolling basis	Dependent upon proposal	https://www.grants.gov/web/grants/view-opportunity.html?opId=305996
21.	Dept. of the Army, USAMRAA – BAA for Extramural Biomedical Research and Development (DoD)	W81XW H-18-S-SOC1	<p>A primary emphasis of the USSOCOM Biomedical, Human Performance, and Canine Research Program is to identify and develop techniques, knowledge products, and materiel (medical devices, drugs, and biologics) for early intervention in life-threatening injuries, prolonged field care (PFC), human performance optimization, and canine medicine/performance. Special Operations Forces (SOF) medical personnel place a premium on medical equipment that is small, lightweight, ruggedized, modular, multi-use, and designed for operation in extreme environments. The equipment must be easy to use, require minimum maintenance, and have low power consumption. Drugs and biologics should not require refrigeration or other special handling. All materiel and related techniques must be simple and effective, and easily modified for commercialization. Research projects may apply existing scientific and technical knowledge for which concept and/or patient care efficacy have already been demonstrated to meet SOF requirements.</p>	<p>Submissions accepted through 7/31/23</p> <p>Submission of a pre-proposal is required</p>	Dependent upon proposal	https://www.grants.gov/web/grants/view-opportunity.html?opId=307754

22.	Polyplexus Pilot, DARPA - Defense Sciences Office (DoD)	HR001118S0058	<p style="text-align: center;">BROAD AGENCY ANNOUNCEMENTS</p> <p>The Defense Sciences Office (DSO) at the Defense Advanced Research Projects Agency (DARPA) is seeking participants for a pilot program designed to utilize modern connectivity to rapidly develop promising basic research pathways and then efficiently develop basic research proposals. This announcement is intended to support the DSO mission to anticipate scientific surprise. Polyplexus is an online platform being developed under the DARPA Gamifying the Search for Strategic Surprise (GS3) program. This BAA, Polyplexus Pilot 2, will pilot test the Polyplexus platform. The goal of the Polyplexus platform is to fundamentally reshape the research and development (R&D) process by significantly reducing the time between concept emergence and worthy proposal submission. The Polyplexus platform aims to achieve this goal via efficiency gains that arise from collaborative activities focused on rigorous evidence collection and hypothesis generation, both of which are facilitated by online conversation.</p>	<p>Abstract Due: 8/14/19</p> <p>Proposal Due: 9/3/19</p>	Dependent upon proposal	https://www.fbo.gov/index.php?s=opportunity&mode=form&id=5d9336ebd5c1d4c99138e908433891bf&tab=core&tabmode=list&
23.	Military Medical Photonics Program - Air Force Office of Scientific Research (DoD)	FA9550-19-S-0004	<p>The Air Force Office of Scientific Research (AFOSR) seeks unclassified proposals for broad-based research and development aimed at using lasers and other light source technology to develop applications in medicine, photobiology, surgery, and closely related materials sciences, with applications to combat casualty care and other military medical problems. This announcement is primarily directed toward university-based medical institutions; however, all qualified and responsible prime applicants located in the United States are eligible to submit proposals. The highest priority will be extended to proposals up to three (3) years duration to be conducted by teams of physicians, biomedical scientists, physical scientists, and engineers. The efforts proposed may be basic or applied research and must have direct relevance to combat casualty care or other military medical priorities. Applicants must demonstrate substantial experience working to further military medical priorities, including transitioning research into clinical practice and working products. Substantial experience collaborating with military medical centers is also a requirement to establish relevance to combat casualty care or other military medical priorities and facilitate the transition of research results to meet military needs.</p>	Proposal Due: 6/30/19	Dependent upon proposal, for up to 3 years	https://www.grants.gov/web/grants/view-opportunity.html?oppld=314819 <p>(Full Announcement in Related Documents Tab)</p>

24.	Army Applications Lab BAA for Disruptive Applications (DoD)	W911NF-19-S-0004	<p style="text-align: center;">BROAD AGENCY ANNOUNCEMENTS</p> <p>AAL is interested in any and all technologies which can be shown to enable the Army of 2028 to be ready to deploy, fight, and win decisively against any adversary, anytime, and anywhere, in a joint, multi-domain, high-intensity conflict, while simultaneously deterring others and maintaining its ability to conduct irregular warfare. AAL is seeking technologies that address a wide range of Army needs consistent with CFT capability focus areas and associated programs and lines of effort as well as potentially disruptive new capabilities that augment or enhance Army capability overmatch.</p>	<p>Submissions accepted through 5/1/24</p> <p>Submission of a pre-proposal is required</p>	<p>Dependent Upon Proposal</p>	<p>https://www.grants.gov/web/grants/view-opportunity.html?opId=315517</p> <p>(Full Announcement in Related Documents Tab)</p>
25.	Biological Technologies (DARPA) (DoD)	HR001119S0048	<p>This announcement seeks revolutionary research ideas for topics not being addressed by ongoing BTO programs or other published solicitations. The mission of BTO is to foster, demonstrate, and transition breakthrough fundamental research, discoveries, and applications that integrate biology, engineering, computer science, mathematics, and the physical sciences. BTO's investment portfolio goes far beyond life sciences applications in medicine to include areas of research such as human-machine interfaces, microbes as production platforms, and deep exploration of the impact of evolving ecologies and environments on U.S. readiness and capabilities. BTO's programs operate across a wide range of scales, from individual cells to the warfighter to global ecosystems. BTO responds to the urgent and long-term needs of the Department of Defense (DoD) and addresses national security priorities.</p>	<p>Proposal Due: 4/23/20</p> <p>Proposals accepted on a rolling basis</p>	<p>Dependent upon proposal</p>	<p>https://www.fbo.gov/index?s=opportunity&mode=form&id=107ff792d860276890c1d3dcd364c661&tab=core&_cvview=1</p>
26.	ReVector (DARPA) (DoD)	HR001119S0056	<p>The ReVector program aims to develop methods to use human skin microbiomes to modulate chemical signatures in order to avoid mosquito attraction and feeding and reduce the threat of mosquito-borne disease to Warfighters. Human skin associated microbes interact with metabolites from the body and influence the personal chemical signature of each individual, making some individuals more attractive to mosquitoes. This program seeks to develop advanced data analytics and microbiome modulation tools for engineering skin microbiomes and provide new options for the readiness and resiliency of military personnel.</p>	<p>Proposal due: 7/11/19</p>	<p>Dependent upon proposal</p>	<p>https://www.fbo.gov/index?s=opportunity&mode=form&id=422aabffab745a540624671e1d9d9316&tab=core&_cvview=1</p>

27.	BAA for Private Sector Partnership Addressing Emerging Zoonoses and Antimicrobial Resistance (USAID)	GH-BAA-2018-ADDEN DUM02	<p align="center">BROAD AGENCY ANNOUNCEMENTS</p> <p>The challenge is to develop and implement innovative, market-driven, and sustainable R&D solutions that substantially advance progress in achieving both increasing global access to safe, affordable, high quality animal-source nutrition and global health security through prevention of emerging zoonoses, trans-boundary animal diseases, and AMR. Solutions should focus on the nexus between public and private sector collaboration and should add value to existing—or develop new—approaches that are beyond the capacity of the public sector to achieve independently. Solutions should further account for trends, policy environments, and capacities that differ geographically, where relevant, while exploiting approaches with potential for wide scale applicability.</p>	Proposal Due: 6/24/19	Dependent upon proposal, for up to 5 years	https://www.grants.gov/web/grants/view-opportunity.html?oppId=315989 (Full Announcement in Related Documents Tab)
28.	Renewal Application: Critical Path Public Private Partnerships (U18) Clinical Trials Optional (NIH)	RFA-FD-19-027	As part of its Critical Path Initiative, FDA recognizes the need for collaborations established under the terms and conditions of a cooperative agreement to facilitate Critical Path Public-Private Partnerships / Consortia activities. This includes developing innovative, collaborative projects in research, education, and outreach for fostering medical product innovation, enabling the acceleration of medical product development, manufacturing, and translational therapeutics, and enhancing medical product safety.	Proposal Due: 7/29/19	Up to \$20 million per year, for up to 5 years	https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-19-027.html#_Section_II_Award_1
CANCER (10)						
29.	Provocative Questions (PQs) in Multiple Myeloma Disparities Research (R01 & R21 Clinical Trial Optional) (NIH)	PAR-19-279 (R01) PAR-19-280 (R21)	The purpose of this FOA is to invite applications for research projects designed to solve specific problems and paradoxes in multiple myeloma (MM) and disparities research identified by the National Cancer Institute (NCI) as the NCI's Multiple Myeloma Disparities Provocative Questions (MMD PQs). These problems and paradoxes phrased as questions are not intended to represent the full range of NCI's priorities in multiple myeloma research. Rather, they are meant to challenge cancer researchers to think about and elucidate specific problems in key areas of multiple myeloma and disparities research that are deemed important but have not received sufficient attention. The FOA includes 6 Multiple Myeloma PQs that represent diverse fields relevant to multiple myeloma disparities research, but all are framed to inspire interested scientists to conceive new approaches and/or feasible solutions.	Proposal Due: 7/15/19 11/15/19	Dependent upon proposal, for up to 5 years (R01) Up to \$275,000, for up to 2 years (R21)	https://grants.nih.gov/grants/guide/pa-files/PAR-19-279.html (R01) http://grants.nih.gov/grants/guide/pa-files/PAR-19-280.html (R21)

30.	NCI Research Specialist (Core-based Scientist & Lab-based Scientist) Award (R50 Clinical Trial Not Allowed) (NIH)	PAR-19-290 (CBS) PAR-19-291 (LBS)	<p style="text-align: center;">CANCER</p> <p>This FOA invites grant applications for the Research Specialist Award (R50) in any area of NCI-funded cancer research. This FOA is specifically for core/shared resource/central scientific support scientists. The Research Specialist Award is designed to encourage the development of stable research career opportunities for exceptional scientists who want to continue to pursue research within the context of an existing NCI-funded basic, translational, clinical, or population science cancer research program, but not serve as independent investigators.</p>	Letter of Intent Due: 9/18/19 Proposal Due: 10/18/19	Dependent upon proposal, for up to 5 years	https://grants.nih.gov/grants/guide/pa-files/PAR-19-290.html (CBS) http://grants.nih.gov/grants/guide/pa-files/PAR-19-291.html (LBS)
31.	FY19 Melanoma Research Program (MRP) (CDMRP/DoD)	W81XW H-19-MRP-IA; TSA; TRA	The MRP challenges the research community to redefine the concept of prevention and looks to shift the paradigm of prevention of all types of melanoma by investing in research studies focused on eliminating the progress of this deadly disease whether it is cutaneous melanoma or a rare subtype.	Letter of Intent Due: 7/26/19 Proposal Due: 10/23/19	Up to \$700,000, for up to 3 years Dependent upon award mechanism	https://cdmrp.army.mil/funding/mrp
32.	FY19 Kidney Cancer Research Program (KCRP) (CDMRP/DoD)	W81XW H-19-KCRP-CA; IDA; TRPA	The FY19 KCRP Concept Award supports highly innovative, untested, potentially groundbreaking novel concepts in kidney cancer. The KCRP's vision is to eliminate kidney cancer through collaboration and discovery. The KCRP's mission is to promote rigorous, innovative, high-impact research in kidney cancer for the benefit of Service members, Veterans, and the American public.	Letter of Intent Due: 9/17/19 Proposal Due: 10/1/19	Up to \$600,000, for up to 3 years Dependent upon award mechanism	https://cdmrp.army.mil/funding/kcrp

			CYBER SECURITY/INFRASTRUCTURE (1)			
33.	FY19 Funding Opportunity Announcement (FOA) for the Office of Naval Research (ONR) Navy ROTC Cybersecurity Training Program (DoD)	N00014-19-S-F009	The ONR seeks a broad range of applications for augmenting existing or developing innovative solutions that directly maintain, or cultivate a diverse, world-class STEM workforce in order to maintain the U.S. Navy and Marine Corps' technological superiority. The goal of any proposed effort must provide solutions that will grow a capable and trained workforce with the skills to defend against emergent cyber and electronic warfare threats. Funding efforts will be targeted primarily toward projects addressing the technical skills taught to university students enrolled in ROTC programs; these ROTC programs are not restricted to any particular Service. While this effort is targeted primarily toward students enrolled in ROTC programs it can also include civilian students.	Proposals accepted on a rolling basis until June 2020	Dependent upon proposal	https://www.onr.navy.mil/en/work-with-us/funding-opportunities/announcements
			DIABETES, DIGESTIVE AND KIDNEY DISEASES (1)			
34.	Early-Stage Preclinical Validation of Therapeutic Leads for Diseases of Interest to the NIDDK (R01 Clinical Trial Not Allowed) (NIH)	PAR-19-294	The goal of this FOA is to support translational research that provides strong justification for later-phase therapeutics discovery and development efforts in health-related outcomes relevant to the National Institute of Diabetes and Digestive and Kidney Diseases. This includes outcomes relevant to obesity, diabetes and related aspects of endocrinology and metabolism, digestive diseases, liver diseases, nutrition, kidney and urological diseases, and hematology.	Letter of Intent Due: 10/12/19 Proposal Due: 11/12/19	Dependent upon proposal, for up to 5 years	https://grants.nih.gov/grants/guide/pa-files/PAR-19-294.html

GENETICS (3)						
35.	The Electronic Medical Records and Genomics (eMERGE): Genomic Risk Assessment and Management Network - Coordinating Center, Clinical Sites, and Enhanced Diversity Clinical Sites (U01 Clinical Trial Required) (NIH)	RFA-HG-19-015 (CC) RFA-HG-19-013 (CS) RFA-HG-19-014 (EDCS)	The purpose of this FOA is to continue genomic implementation research in the Electronic Medical Records and Genomics (eMERGE) Network by through the development of a coordinating center, clinical sites, and enhanced diversity clinical sites.	Letter of Intent Due: 7/2/19 Proposal Due: 8/2/19	Dependent upon proposal and award mechanism, for up to 5 years	https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-19-015.html (CC) https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-19-013.html (CS) https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-19-014.html (EDCS)
HEARING (1)						
36.	FY19 Hearing Restoration Research Program (HRRP) (CDMRP/DoD)	W81XWH-19-HRRP-FRA	The HRRP will fund innovative research that has the potential to maximize operational effectiveness, medical readiness and quality of life for Service members, Veterans and others living with significant auditory system injuries.	Letter of Intent Due: 7/16/19 Proposal Due: 11/14/19	Up to \$1.25 million, for up to 3 years	https://cdmrp.army.mil/funding/hrrp

HEART, LUNG AND BLOOD (3)							
37.	Advancing Novel Research Models to Study Idiopathic Pulmonary Fibrosis (U01 Clinical Trial Not Allowed) (NIH)	RFA-HL-20-007	The purpose of this FOA is to establish a set of complementary model systems that reproduce essential disease-defining features of human idiopathic pulmonary fibrosis (IPF). This collection of models will advance our understanding of the pathogenesis of IPF from its onset through disease progression and serve as a resource for the broader research community, including investigators developing and testing novel therapies to treat this fatal disease.	Letter of Intent Due: 9/1/19 Proposal Due: 10/1/19	Dependent upon proposal, for up to 4 years	https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-20-007.html	
38.	Cardiovascular Developmental Biology Data Resource Center (U01 - Clinical Trial Not Allowed) (NIH)	RFA-HL-20-017	The objective of this FOA is to support the development of the Data Resource Center for the basic science component of the NHLBI Bench to Bassinet (B2B) Program. The goal of the Data Resource Center is to accelerate discovery of genetic etiology and biologic pathways associated with cardiovascular development and congenital heart disease by facilitating access to and querying of annotated data from cardiovascular development studies.	Letter of Intent Due: 9/2/19 Proposal Due: 10/2/19	Dependent upon proposal, for up to 5 years	https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-20-017.html	
39.	Pediatric Cardiac Genomics Consortium (U01 Clinical Trial Not Allowed) (NIH)	RFA-HL-20-015	The purpose of this FOA is to invite applications to participate as a Research Center in the Pediatric Cardiac Genomics Consortium (PCGC). The PCGCs mission is to identify genetic causes of human congenital heart disease (CHD) and to relate genetic variants in patients with CHD to clinical outcomes through collaborative, multi-center studies. The PCGC fosters investigation along the translational spectrum of CHD research through interactions with Cardiovascular Development Data Resource Center (CDDRC, previously the Cardiovascular Development Consortium) and the Pediatric Heart Network (PHN).	Letter of Intent Due: 9/2/19 Proposal Due: 10/2/19	Up to \$275,000 per year, for up to 5 years	https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-20-015.html	

IMMUNOLOGY (2)						
40.	Immunobiology of Xeno-transplantation (U19 & U01 Clinical Trial Not Allowed) (NIH)	RFA-AI-19-043 (U19) RFA-AI-19-042 (U01)	This FOA invites applications from institutions to participate in the Immunobiology of Xenotransplantation Cooperative Research Program (IXCRP), for the development of preclinical porcine-to-nonhuman primate (NHP) models of pancreatic islet, kidney, heart, lung, or liver xenotransplantation. The goals of this program are to: (1) delineate the cellular and molecular mechanisms of xenograft rejection and/or the induction of immune tolerance; (2) develop effective strategies to improve xenograft survival; and (3) characterize and address the physiological compatibility/limitations of xenografts. The long-term goal of this program is to develop strategies for application of xenotransplantation in the clinic.	Letter of Intent Due: 8/16/19 Proposal Due: 9/16/19	Dependent upon proposal, for up to 5 years	https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-19-043.html (U19) https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-19-042.html (U01)
INFECTIOUS DISEASE (3)						
41.	NIAID Clinical Trial Planning Grant (R34 Clinical Trial Not Allowed) (NIH)	PAR-19-281	This FOA encourages applications that propose the complete planning, design, and preparation of the documentation necessary for implementation of investigator-initiated clinical trials. The trials should be hypothesis-driven, milestone-defined, related to the research mission of the NIAID and considered high priority by the Institute.	Letter of Intent Due: 8/13/19 Proposal Due: 9/13/19	Up to \$150,000, for up to 1 year	https://grants.nih.gov/grants/guide/par-files/PAR-19-281.html
42.	NIAID New Innovators Awards (DP2 Clinical Trial Not Allowed) (NIH)	PAR-19-296	The NIAID New Innovator Awards supports post-doctoral and early stage investigators of exceptional creativity who propose highly innovative bold new research with the potential to produce a major impact on broad, important problems in biomedical research of priority to NIAID.	Letter of Intent Due: 9/10/19 Proposal Due: 10/10/19	Up to \$300,000 per year, for up to 5 years	https://grants.nih.gov/grants/guide/par-files/PAR-19-296.html

43.	Innovations in Malaria Vaccine Development (IMV) (USAID)	GH-BAA-2018-ADDENDUM03	<p style="text-align: center;">INFECTIOUS DISEASE</p> <p>USAID is seeking to enhance our malaria vaccine investments through a collaborative design process. The goal of USAID’s Malaria Vaccine Development Program (MVDP) is to demonstrate the proof of concept of a vaccine to reduce morbidity and mortality due to malaria caused by infection with Plasmodium falciparum. Target malaria vaccine end characteristics will include at least 75% efficacy and evidence of affordability. USAID intends to support efforts towards vaccines that have the potential to directly protect recipients against disease caused by P. falciparum such as vaccines that target the pre-erythrocytic (sporozoite and liver stage) and erythrocytic stages of the life cycle. The purpose of this Addendum is to solicit Expressions of Interest (EOI) for novel and innovative approaches to malaria vaccine development that would encompass preclinical development through proof of principle clinical studies to motivate advanced development of a deployable, effective malaria vaccine.</p>	Proposal Due: 6/21/19	Dependent upon proposal, for up to 5 years	<p>https://www.grants.gov/web/grants/view-opportunity.html?opId=316074</p> <p>(Full Announcement in Related Documents Tab)</p>
			NERVOUS SYSTEM (4)			
44.	Centers Without Walls for Collaborative Research in the Epilepsies: Functional Evaluation of Human Genetic Variants (U54 Clinical Trial Not Allowed) (NIH)	RFA-NS-19-019	The purpose of this FOA is to encourage cooperative agreement (U54) applications from multidisciplinary groups of investigators to accelerate the rate of progress in determining the functional, pharmacological, neuronal network and whole animal consequences of genetic variants discovered in patients with various types of epilepsy and to develop strategies for establishing diagnostic criteria and identifying potential targets for intervention.	Letter of Intent Due: 7/27/19 Proposal Due: 8/27/19	Up to \$1.5 million per year, for up to 5 years	https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-19-019.html

45.	Brain Initiative: Research to Develop and Validate Advanced Human Cell-Based Assays To Model Brain Structure and Function (R01 Clinical Trial Not Allowed) (NIH)	RFA-MH-20-140	<p style="text-align: center;">NERVOUS SYSTEM</p> <p>This FOA encourages research grant applications directed toward developing next-generation human cell-derived assays that replicate complex nervous system architectures and physiology with improved fidelity over current capabilities. This includes technologies that do not rely on the use of human fetal tissue, as described in NOT-19-042. Supported projects will be expected to enable future studies of complex nervous system development, function and aging in healthy and disease states.</p>	Letter of Intent Due: 10/1/19 Proposal Due: 11/1/19	Up to \$500,000 per year, for up to 3 years	https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-20-140.html
46.	FY19 Epilepsy Research Program (ERP) (CDMRP/DoD)	W81XWH-19-ERP-IDA; RPA	The goal of FY19 ERP is to support innovative, high-impact epilepsy research. ERP encourages applications that address the critical needs of the epilepsy community in one or more of the following FY19 Focus Areas: Hardware and/or software platforms that will improve seizure detection, characterization, or diagnosis; Bioinformatics strategies, to include machine learning, that will improve access, annotation, curation and visualization of large and novel datasets from single or multiple sources; Development of new models or better characterization of existing etiologically relevant models for PTE; and Improved characterization of the circuits involved in PTE.	Letter of Intent Due: 5/26/19 Proposal Due: 7/17/19	Up to \$1.3 million, for up to 3 years Dependent upon award mechanism	https://cdmrp.army.mil/funding/erp
NEUROSCIENCE (7)						
47.	Building in vivo Preclinical Assays of Circuit Engagement for Application in Therapeutic Development (R01 Clinical Trial Not Allowed) (NIH)	PAR-19-289	The overall goal of this FOA is to identify, in animals, in vivo neurophysiological and behavioral measures for use as assays in the early screening phase of treatment development. The FOA will support efforts to optimize and evaluate measures of neurophysiological and behavioral processes that may serve as surrogate markers of neural processes of clinical interest based on available knowledge of the neurobiology of mental illnesses. The screening assays thus developed from this FOA are expected to build upon systems neurobiology and clinical neuroscience to enhance the scientific value of preclinical animal data contributing to a therapeutic development pipeline by assessing the impact of therapeutic targets and treatment candidates on neurobiological mechanisms of clinical relevance to mental illnesses.	Proposal Due: 10/5/19	Dependent upon proposal, for up to 5 years	https://grants.nih.gov/grants/guide/pa-files/PAR-19-289.html

48.	Research Program Award (R35 Clinical Trial Optional) (NIH)	RFA-NS-19-037	<p style="text-align: center;">NEUROSCIENCE</p> <p>The purpose of the NINDS Research Program Award (RPA) is to provide longer-term support and increased flexibility to Program Directors (PDs) /Principal Investigators (PIs) whose records of research achievement demonstrate their ability to make major contributions to neuroscience. RPAs will support the overall research programs of NINDS-funded investigators for up to 8 years, at a level commensurate with a PD/PI's recent NINDS support (Part 2, Section II) This greater funding stability will provide eligible investigators at nearly all career stages increased freedom and flexibility, allowing them to be more adventurous in their research, take greater risks, embark upon research that breaks new ground, undertake research projects that require a longer timeframe, and/or extend previous discoveries in new directions. Research supported through the RPA must be within the scope of the NINDS mission.</p>	<p>Letter of Intent Due: 6/30/19</p> <p>Proposal Due: 7/30/19</p>	Up to \$750,000 per year, for up to 8 years	https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-19-037.html
49.	Notice of Intent to Publish a Funding Opportunity Announcement for Consortium on the Neurobiology of Adolescent Drinking in Adulthood (NADIA) Research Projects (U01 & U24) (Clinical Trial Not Allowed) (NIH)	<p>NOT-AA-19-016 (U01)</p> <p>NOT-AA-19-017 (U24)</p>	<p>The National Institute on Alcohol Abuse and Alcoholism (NIAAA) intends to renew an initiative by publishing a FOA to solicit applications for collaborative research projects (U01) to investigate persistent changes in complex brain function-behavior relationships following adolescent alcohol exposure. The U01s are components of the Consortium on the Neurobiology of Adolescent Drinking in Adulthood (NADIA). This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects.</p>	Estimated Release Date: October 2019	Dependent upon proposal	<p>https://www.grants.gov/web/grants/view-opportunity.html?opId=316662 (U01)</p> <p>https://www.grants.gov/web/grants/view-opportunity.html?opId=316663 (U24)</p>

50.	Notice of Intent to Publish a Funding Opportunity Announcement for BRAIN Initiative: Development of Next Generation Human Brain Imaging Tools and Technologies (U01 & R01 Clinical Trial not allowed) (NIH)	NOT-EB-19-011 (U01) NOT-EB-19-010 (R01)	NEUROSCIENCE The NIH Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative intends to reissue RFA-EB-17-004, Development of Next Generation Human Brain Imaging Tools and Technologies, with modifications. This FOA aims to support full development of entirely new or next generation noninvasive human brain imaging tools and methods that will lead to transformative advances in our understanding of the human brain. The FOA seeks innovative applications that are ready for full-scale development of breakthrough technologies with the intention of delivering working tools.	Estimated Release Date: June 2019	Dependent upon proposal	https://www.grants.gov/web/grants/view-opportunity.html?opId=316668 (U01) https://www.grants.gov/web/grants/view-opportunity.html?opId=316667 (R01)
51.	FY19 Psychological Health/Traumatic Brain Injury Research Program (PH/TBIRP) (CDMRP/DoD)	W81XW H-19-PHTBIR-FITBIRA	The JPC-6/CCCRP Neurotrauma Portfolio's mission is focused on closing military-relevant gaps across a broad range of research areas to improve the prevention, diagnosis, management, and treatment of TBI and related sequelae from point of injury through recovery. The goal is to decrease morbidity and mortality from neurotrauma, mitigate secondary brain injury across all TBI severities and all roles of care, advance materiel and knowledge development, and expand and develop clinical guidelines, care algorithms, therapies, devices, and procedures that advance the decision-making capabilities of medical personnel, enabling earlier intervention and improved outcomes.	Letter of Intent Due: 7/10/19 Proposal Due: 8/1/19	Up to \$750,000, for up to 1.5 years	https://cdmrp.army.mil/funding/phtbi
OPIOIDS (2)						
52.	Forecasted Opportunity: Rural Communities Opioid Response Program - Implementation (HRSA)	HRSA-20-031	The purpose of Rural Communities Opioid Response Program-Implementation (RCORP-Implementation) is to support treatment for and prevention of substance use disorder, including opioid use disorder (OUD), with a focus on rural communities at the highest risk for substance use disorder.	Estimated release date: January 2020	Dependent upon proposal	https://www.grants.gov/web/grants/view-opportunity.html?opId=315880

53.	Exploiting In Vivo Precision Pharmacology Techniques to Understand Opioid Receptor Signaling in Specific Circuits, Cell Types, and Subcellular Compartments (R61/R33 Clinical Trial Not Allowed) (NIH)	RFA-DA-20-019	<p style="text-align: center;">OPIOIDS</p> <p>This FOA aims to support the development and the application of novel pharmacological approaches to manipulate signaling mediated by endogenous opioid receptors in defined circuits, cell-types or subcellular compartments in live organisms.</p>	<p>Letter of Intent Due: 9/17/19</p> <p>Proposal Due: 10/17/19</p>	<p>Dependent upon proposal, for up to 5 years</p>	<p>https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-20-019.html</p>
			RARE DISEASES (1)			
54.	Rare Disease Clinical Outcome Assessment Consortium (U01 Clinical Trial Not Allowed)	RFA-FD-19-029	<p>This cooperative agreement will provide funding to establish a rare disease consortium focusing on clinical outcome assessments appropriate for use in drug development to demonstrate clinical benefit. Many rare diseases include neurodegenerative decline resulting in loss of ability to perform daily activities. Therefore, domains of interest include, but are not limited to, cognition, adaptive behavior, physical function (e.g., fine motor function, ambulation, speech, swallowing) and assessments of patients' ability to perform activities of daily living. Special considerations that should be addressed include the fact that many rare diseases affect children as well as adults and trials are often multiregional, which necessitates attention to cross-cultural considerations. The final outcome would be the creation of a common resource describing publicly available fit-for-purpose clinical outcome assessments as well as accompanying information, such as the populations for use and the strengths and limitations of each tool.</p>	<p>Proposal Due: 7/29/19</p>	<p>Up to \$300,000, for up to 1 year</p>	<p>https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-19-029.html</p>

RECONSTRUCTIVE TRANSPLANT (2)						
55.	FY19 Reconstructive Transplant Research Program (RTRP) (CDMRP/DoD)	W81XW H-19- RTRP- IDA; IIRA	The RTRP challenges the scientific community to design innovative research that will optimize form, function, appearance, and psychosocial health for catastrophically injured Service members, Veterans, and American civilians through the development of effective reconstructive transplantation solutions. More specifically, the RTRP seeks vascularized composite allotransplantation (VCA)-focused research, also known as composite tissue allotransplantation. VCA refers to the transplantation of multiple tissues such as muscle, bone, nerve, and skin, as a functional unit (e.g., a hand or face) from a deceased donor to a recipient with a severe injury. The ultimate goal is to return injured Service members to duty and restore their quality of life.	Letter of Intent Due: 7/17/19 Proposal Due: 10/16/19	Up to \$1.5 million, for up to 3 years Dependent upon award mechanism	https://cdmrp.army.mil/funding/rtrp
REGENERATIVE MEDICINE (1)						
56.	Notice of Intent to Publish the Reissuance of Regenerative Medicine Innovation Project (RMIP) Investigator- Initiated Clinical Trials (UG3/UH3 – Clinical Trial Required)	NOT-HL- 19-700	The National Institutes of Health (NIH) and participating NIH Institutes and Centers (ICs) and the U.S. Food and Drug Administration (FDA) intend to reissue RFA-HL-18-031 for new applications that will support investigator-initiated clinical trials aimed at furthering the field of regenerative medicine (RM) using adult stem cells. Applicants must apply and undergo peer review. In order to fulfill the mandate of advancing the field of RM more broadly, the reissued FOA is intended to support projects that propose solutions to widely recognized issues in the development of safe and effective RM therapies.	Estimated Release Date: July 2019	Dependent upon proposal	https://www.grants.gov/web/grants/view-opportunity.html?opId=316666

SBIR/STTR (1)						
57.	Methods to Improve Reproducibility of Human iPSC Derivation, Growth and Differentiation (SBIR) (R44 Clinical Trial Not Allowed) (NIH)	RFA-GM-19-001	This FOA will support SBIR projects to develop novel, reliable and cost-effective methods to standardize and increase the utility and reproducibility of iPSCs (induced pluripotent stem cells) at all stages, from their derivation to their research and clinical applications.	Proposal Due: 1/6/20	Up to \$375,000 per year, for up to 2 years	https://grants.nih.gov/grants/guide/rfa-files/RFA-GM-19-001.html
STEM/ICT (1)						
58.	Innovative Technology Experiences for Students and Teachers (NSF)	NSF-19-583	ITEST is an applied research and development (R&D) program providing direct student learning opportunities in pre-kindergarten through high school (PreK-12). The learning opportunities are based on innovative use of technology to strengthen knowledge and interest in science, technology, engineering, and mathematics (STEM) and information and communication technology (ICT) careers. To achieve this purpose, ITEST supports projects that engage students in technology-rich experiences that: (1) increase awareness and interest of STEM and ICT occupations; (2) motivate students to pursue appropriate education pathways to those occupations; and (3) develop STEM-specific disciplinary content knowledge and practices that promote critical thinking, reasoning, and communication skills needed for entering the STEM and ICT workforce of the future. ITEST seeks proposals that pursue innovative instructional approaches and practices in formal and informal learning environments, in close collaboration with strategic partnerships. ITEST proposals should broaden participation of all students, particularly those in underrepresented and underserved groups in STEM fields and related education and workforce domains. ITEST supports three types of projects: (1) Exploring Theory and Design Principles (ETD); (2) Developing and Testing Innovations (DTI); and (3) Scaling, Expanding, and Iterating Innovations (SEI). ITEST also supports Synthesis and Conference proposals.	Proposal Due: 8/19/19	Dependent upon proposal	https://www.nsf.gov/publications/pub_summ.jsp?ods_key=nsf19583

VISION (3)						
59.	FY19 Vision Research Program (VRP) (CDMRP/DoD)	W81XW H-19-VRP-FTTSA; IIRA; TRA	The VRP has identified two near- and medium-term program priorities: 1) Accelerate research in eye injury and vision dysfunction due to military-relevant trauma and 2) Advance diagnosis and treatment of eye injuries in both a forward operating environment and a prolonged field care setting. The VRP is uniquely focused, as well as uniquely positioned, to promote research that addresses current and anticipated battlefield-related eye and vision injuries. To preserve the eyesight of injured Warfighters, we must achieve a better understanding of the biological, physical, and mechanical mechanisms by which military-relevant trauma damages the ocular system and impairs vision, as well as develop more effective preventive and treatment approaches.	Letter of Intent Due: 8/6/19 Proposal Due: 12/6/19	Up to \$5 million, for up to 4 years Dependent upon award mechanism	https://cdmrp.army.mil/funding/vrp
ORTHOPAEDIC (3)						
60.	FY19 Peer Reviewed Orthopaedic Research Program (PRORP) (CDMRP/DoD)	W81XW H-19-PRORP-ARA; CTA; CTRA	The PRORP was established to support military-relevant, peer-reviewed orthopaedic research with potential to provide healthcare solutions for the injured Service member, Veteran, and civilian. A large majority of the injuries sustained by military personnel in U.S. combat efforts involve soft tissue wounds and skeletal fractures, pointing to an urgent need for orthopaedic research that will provide superior medical care and treatment options for injured Service members. Orthopaedic injuries sustained during combat-related activities tend to be heterogeneous and complex in nature, typically involving multiple tissues, such as skin, bone, muscle, cartilage, and nerves. These injuries are sustained in harsh environments where access to optimal acute care can be limited, and they are distinct from those seen in the civilian setting, frequently involving multiple limb trauma, open fractures, major tissue loss, and a high degree of wound contamination.	Letter of Intent Due: 6/26/19 Proposal Due: 9/18/19	Up to \$2.5 million, for up to 4 years Dependent upon award mechanism	https://cdmrp.army.mil/funding/prorp
OTHER (13)						
61.	Forecasted Opportunity: Telehealth Network Program (HRSA)	HRSA-20-036	The purpose of the Telehealth Network Program (TNP) is to demonstrate how telehealth networks are used to: (a) expand access to, coordinate, and improve the quality of health care services; (b) improve and expand the training of health care providers; and/or (c) expand and improve the quality of health information available to health care providers, and patients and their families, for decision-making. In particular, we wish to encourage telehealth services delivered through school-based health centers/clinics (SBHC), particularly those serving high-poverty populations	Estimated release date: January 2020	Dependent upon proposal	https://www.grants.gov/web/grants/view-opportunity.html?oppId=315882

62.	Information Sharing System for State-Regulated Drug Compounding Activities (U01 Clinical Trial Not Allowed) (FDA)	RFA-FD-19-025	OTHER	Letter of Intent Due: 6/3/19 Proposal Due: 7/17/19	Up to \$1.6 million, for up to 3 years	https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-19-025.html
63.	Drug Screening with Biofabricated 3-D Skin Disease Tissue Models (U18 Clinical Trial Not Allowed) (NIH)	RFA-TR-19-020	The purpose of this FOA is to build upon the work that has begun under previous FOA RFA-TR-17-007 NCATS Pilot Program for Collaborative Drug Discovery Research Using Bioprinted Skin Tissue and utilize physiologically relevant and validated 3-D biofabricated skin disease tissue models in multi-well drug screening platforms. The FOA will support intramural- extramural collaborations to implement the use of 3-D biofabricated skin tissue models and provide evidence of success for 3-D drug screening platforms.	Letter of Intent Due: 7/1/19 Proposal Due: 7/31/19	Up to \$400,000 per year, for up to 2 years	https://grants.nih.gov/grants/guide/rfa-files/RFA-TR-19-020.html
64.	Research to Understand and Inform Interventions that Promote the Research Careers of Individuals in the Biomedical Sciences (R01 - Clinical Trial Not Allowed) (NIH)	PAR-19-295	This FOA encourages solicits applications that propose research designed to test training, mentoring, and networking interventions intended to enhance research-oriented individuals' interest, motivation, persistence and preparedness for careers in the biomedical research workforce. Funded projects are expected to produce research findings that will guide the design and implementation of potential interventions in a variety of academic settings and career levels to enhance the diversity of the biomedical research workforce.	Letter of Intent Due: 9/5/19 Proposal Due: 10/5/19	Up to \$250,000 per year, for up to 5 years	https://grants.nih.gov/grants/guide/pa-files/PAR-19-295.html
65.	FY19 Bone Marrow Failure Research Program (BMFRP) (CDMRP/DoD)	W81XWH-19-BMFRP-IDA	The FY19 Defense Appropriation provides \$3 million to the DoD BMFRP to support scientifically meritorious research focused on BMF diseases. Preproposals required; full application submission is by invitation only. Key mechanism elements include: Supports innovative ideas and high- impact approaches based on scientifically sound evidence to move toward the vision to understand and cure BMF; Strong BMF research team; May include relevant preliminary data; Clinical trials will not be supported.	Letter of Intent Due: 6/12/19 (Extension) Proposal Due: 9/5/19	Up to \$325,000, for up to 2 years	https://cdmrp.army.mil/funding/bmfrp

66.	FY19 Duchenne Muscular Dystrophy Research Program (DMDRP) (CDMRP/DoD)	W81XW H-19-DMDRP-IDA	OTHER The goal of FY19 DMDRP is to support innovative, high-impact DMD research. DMDRP encourages applications that address the critical needs of the DMD community in one or more of the following FY19 Focus Areas: Delivery to skeletal muscle and heart; Immunosuppression and other strategies to deal with neutralizing antibodies; Re-dosing; Targeting muscle stem cells; and Cell based therapies.	Letter of Intent Due: 8/21/19 Proposal Due: 12/4/19	Up to \$350,000, for up to 2 years	https://cdmrp.army.mil/funding/pa/FY19-DMDRP-IDA.pdf
67.	FY19 Gulf War Illness Research Program (GWIRP) (CDMRP/DoD)	W81XW H-19-GWIRP-IA; RAA; CEA; TBTA; PPCHA; NIA	The FY19 GWIRP focuses on funding innovative, competitively peer-reviewed research to (1) provide a better understanding of the pathobiology underlying GWI, (2) identify objective markers (biomarkers) for improved diagnosis, and (3) to develop treatments for the complex of GWI symptoms and their underlying causes. Our Vision is to make a significant impact on GWI and improve the health and lives of affected Veterans and their families.	Letter of Intent Due: 7/12/19 Proposal Due: 10/3/19	Up to \$5 million, for up to 4 years Dependent upon award mechanism	https://cdmrp.army.mil/funding/gwirp
68.	FY19 Defense Medical Research and Development Program - Accelerating Innovation in Military Medicine (AIMM) (CDMRP/DoD)	W81XW H-19-DMRDP-AIMM	The goal of FY19 Accelerating Innovation in Military Medicine (AIMM) award is to support innovative, high-impact medical research. AIMM encourages applications that address the critical needs of the military community in one or more of the following FY19 Focus Areas: Algorithms/tools for decision support in a deployed or operational environment to: diagnose military-relevant disease, illness, or injury; prescribe mitigation and treatment strategies; and/or determine risk of Warfighter return to duty; Artificial Intelligence (AI)/deep learning for integrating heterogeneous data streams and analyzing data from wearables to support making informed healthcare decisions. Wearable sensor systems may pertain to, but are not limited to, the following or combinations of the following: infectious disease diagnosis; physiologic status monitoring; informing real-time casualty location and triage; and/or environmental monitoring; and AI/deep learning for analyzing and interrogating large medical data sets to: identify patterns/predictors of disease, illness, or injury; and/or identify treatment outcomes.	Letter of Intent Due: 7/26/19 Proposal Due: 10/30/19	Up to \$350,000, for up to 1.5 years	https://cdmrp.army.mil/funding/pa/FY19-DMRDP-AIMM.pdf